Recruitment underway to bring additional leading scientists to expanding GU cancer research program at Cleveland Clinic.
Cleveland Clinic researchers cover the gamut when it comes to prostate cancer investigation, from elucidating mechanisms behind resistance to therapy to developing more precise diagnostics.
A Cleveland Clinic research team finds that tumors in a single prostate can be very diverse, leading to the question: Is sampling the largest, most established or accessible tumor is the best approach?
Androgen deprivation therapy, which prevents androgen receptor signaling, initially is effective against advanced prostate cancer but progression eventually resumes, relying on androgen receptor’s transcriptional activity. Cleveland Clinic researchers are exploring new approaches that block this transactivation function, which may prevent or overcome resistance.
“Big data” genomic projects are helping researchers to begin isolating the androgen receptor action that drives prostate cancer to the lethal stage, providing an entirely novel target for therapy.